Humanity & Health Medical Group Limited
People's Republic of China
- Country
- People's Republic of China
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.hnhmgl.com/en/
Clinical Trials
9
Active:0
Completed:3
Trial Phases
2 Phases
Phase 2:3
Phase 4:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (60.0%)Phase 4
2 (40.0%)Liver Injury After COVID-19 Vaccination
Completed
- Conditions
- Subjects After COVID-19 Vaccination
- Interventions
- Biological: Approved COVID-19 vaccine
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Humanity & Health Medical Group Limited
- Target Recruit Count
- 379
- Registration Number
- NCT05470894
- Locations
- 🇭🇰
Humanity & Health Medical Group Limited, Hong Kong, Hong Kong
🇯🇵Nihon University School of Medicine, Tokyo, Japan
🇯🇵Tokyo University, Tokyo, Japan
A Study to Evaluate Vaccines Against COVID-19 in the Real World
Withdrawn
- Conditions
- Hepatic CarcinomaChronic Liver Disease
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Humanity & Health Medical Group Limited
- Registration Number
- NCT04775056
- Locations
- 🇭🇰
Humanity & Health Medical Group, Hong Kong, Hong Kong
Antibody Response to COVID-19 Vaccines in Liver Disease Patients
Phase 4
Completed
- Conditions
- Chronic Liver Disease
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Humanity & Health Medical Group Limited
- Target Recruit Count
- 232
- Registration Number
- NCT04775069
- Locations
- 🇭🇰
Humanity & Health Medical Group Limited, Hong Kong, Hong Kong
Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Humanity & Health Medical Group Limited
- Target Recruit Count
- 17
- Registration Number
- NCT04428437
- Locations
- 🇭🇰
Humanity & Health Clinical Trial Centre, Hong Kong, Hong Kong SAR, Hong Kong
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Phase 2
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Humanity & Health Medical Group Limited
- Target Recruit Count
- 30
- Registration Number
- NCT03899428
- Locations
- 🇭🇰
Humanity & Health Research Centre, Hong Kong, Hong Kong SAR, Hong Kong
- Prev
- 1
- 2
- Next
News
No news found